vs

Side-by-side financial comparison of MainStreet Bancshares, Inc. (MNSB) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

RECURSION PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($35.5M vs $32.8M, roughly 1.1× MainStreet Bancshares, Inc.). On growth, RECURSION PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (681.7% vs -8.8%). MainStreet Bancshares, Inc. produced more free cash flow last quarter ($10.6M vs $-47.3M). Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs -0.7%).

MainStreet Bancshares, Inc. is a US-based bank holding company that provides comprehensive retail and commercial banking services, including deposit products, personal and business loans, mortgage lending, and wealth management solutions. It primarily serves individual consumers, small and medium-sized enterprises, and local community customers through its regional branch network.

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

MNSB vs RXRX — Head-to-Head

Bigger by revenue
RXRX
RXRX
1.1× larger
RXRX
$35.5M
$32.8M
MNSB
Growing faster (revenue YoY)
RXRX
RXRX
+690.5% gap
RXRX
681.7%
-8.8%
MNSB
More free cash flow
MNSB
MNSB
$58.0M more FCF
MNSB
$10.6M
$-47.3M
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
-0.7%
MNSB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MNSB
MNSB
RXRX
RXRX
Revenue
$32.8M
$35.5M
Net Profit
$-108.1M
Gross Margin
55.1%
59.8%
Operating Margin
14.9%
-304.8%
Net Margin
-304.2%
Revenue YoY
-8.8%
681.7%
Net Profit YoY
39.6%
EPS (diluted)
$0.46
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MNSB
MNSB
RXRX
RXRX
Q4 25
$32.8M
$35.5M
Q3 25
$33.6M
$5.2M
Q2 25
$35.4M
$19.2M
Q1 25
$33.9M
$14.7M
Q4 24
$35.9M
$4.5M
Q3 24
$34.5M
$26.1M
Q2 24
$34.2M
$14.4M
Q1 24
$33.3M
$13.8M
Net Profit
MNSB
MNSB
RXRX
RXRX
Q4 25
$-108.1M
Q3 25
$4.5M
$-162.3M
Q2 25
$4.6M
$-171.9M
Q1 25
$2.5M
$-202.5M
Q4 24
$-178.9M
Q3 24
$265.0K
$-95.8M
Q2 24
$2.6M
$-97.5M
Q1 24
$3.3M
$-91.4M
Gross Margin
MNSB
MNSB
RXRX
RXRX
Q4 25
55.1%
59.8%
Q3 25
54.3%
-183.8%
Q2 25
56.2%
-4.9%
Q1 25
51.5%
-48.0%
Q4 24
46.9%
-181.4%
Q3 24
47.1%
53.7%
Q2 24
47.7%
36.2%
Q1 24
49.4%
19.1%
Operating Margin
MNSB
MNSB
RXRX
RXRX
Q4 25
14.9%
-304.8%
Q3 25
16.1%
-3327.6%
Q2 25
16.0%
-916.8%
Q1 25
9.2%
-1297.9%
Q4 24
-4373.3%
-4042.4%
Q3 24
0.3%
-377.1%
Q2 24
8.4%
-697.4%
Q1 24
12.4%
-698.4%
Net Margin
MNSB
MNSB
RXRX
RXRX
Q4 25
-304.2%
Q3 25
13.4%
-3135.3%
Q2 25
13.0%
-894.2%
Q1 25
7.2%
-1373.3%
Q4 24
-3935.5%
Q3 24
0.8%
-367.5%
Q2 24
7.7%
-676.6%
Q1 24
9.9%
-662.4%
EPS (diluted)
MNSB
MNSB
RXRX
RXRX
Q4 25
$0.46
$-0.17
Q3 25
$0.52
$-0.36
Q2 25
$0.53
$-0.41
Q1 25
$0.25
$-0.50
Q4 24
$-2.19
$-0.56
Q3 24
$-0.04
$-0.34
Q2 24
$0.27
$-0.40
Q1 24
$0.36
$-0.39

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MNSB
MNSB
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$743.3M
Total DebtLower is stronger
$9.6M
Stockholders' EquityBook value
$218.6M
$1.1B
Total Assets
$2.2B
$1.5B
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MNSB
MNSB
RXRX
RXRX
Q4 25
$743.3M
Q3 25
$659.8M
Q2 25
$525.1M
Q1 25
$500.5M
Q4 24
$594.4M
Q3 24
$427.6M
Q2 24
$474.3M
Q1 24
$296.3M
Total Debt
MNSB
MNSB
RXRX
RXRX
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$20.5M
Q2 24
$22.9M
Q1 24
Stockholders' Equity
MNSB
MNSB
RXRX
RXRX
Q4 25
$218.6M
$1.1B
Q3 25
$218.4M
$1.0B
Q2 25
$213.5M
$919.1M
Q1 25
$209.6M
$933.9M
Q4 24
$208.0M
$1.0B
Q3 24
$226.1M
$524.6M
Q2 24
$224.7M
$584.4M
Q1 24
$223.1M
$401.2M
Total Assets
MNSB
MNSB
RXRX
RXRX
Q4 25
$2.2B
$1.5B
Q3 25
$2.1B
$1.4B
Q2 25
$2.1B
$1.3B
Q1 25
$2.2B
$1.3B
Q4 24
$2.2B
$1.4B
Q3 24
$2.2B
$726.5M
Q2 24
$2.1B
$775.9M
Q1 24
$2.1B
$557.8M
Debt / Equity
MNSB
MNSB
RXRX
RXRX
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
Q2 24
0.04×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MNSB
MNSB
RXRX
RXRX
Operating Cash FlowLast quarter
$14.8M
$-46.1M
Free Cash FlowOCF − Capex
$10.6M
$-47.3M
FCF MarginFCF / Revenue
32.5%
-133.1%
Capex IntensityCapex / Revenue
12.7%
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$14.9M
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MNSB
MNSB
RXRX
RXRX
Q4 25
$14.8M
$-46.1M
Q3 25
$5.6M
$-117.4M
Q2 25
$1.2M
$-76.4M
Q1 25
$1.5M
$-132.0M
Q4 24
$14.7M
$-115.4M
Q3 24
$4.5M
$-59.2M
Q2 24
$1.2M
$-82.2M
Q1 24
$3.6M
$-102.3M
Free Cash Flow
MNSB
MNSB
RXRX
RXRX
Q4 25
$10.6M
$-47.3M
Q3 25
$5.5M
$-117.6M
Q2 25
$-2.6M
$-79.6M
Q1 25
$1.4M
$-133.8M
Q4 24
$13.8M
$-116.7M
Q3 24
$4.3M
$-63.8M
Q2 24
$1.1M
$-83.4M
Q1 24
$3.0M
$-109.0M
FCF Margin
MNSB
MNSB
RXRX
RXRX
Q4 25
32.5%
-133.1%
Q3 25
16.2%
-2272.5%
Q2 25
-7.4%
-413.9%
Q1 25
4.1%
-907.4%
Q4 24
38.5%
-2567.7%
Q3 24
12.5%
-244.6%
Q2 24
3.1%
-578.5%
Q1 24
9.1%
-789.9%
Capex Intensity
MNSB
MNSB
RXRX
RXRX
Q4 25
12.7%
3.5%
Q3 25
0.4%
4.7%
Q2 25
10.8%
16.4%
Q1 25
0.2%
12.4%
Q4 24
2.5%
28.6%
Q3 24
0.5%
17.5%
Q2 24
0.3%
8.2%
Q1 24
1.8%
48.2%
Cash Conversion
MNSB
MNSB
RXRX
RXRX
Q4 25
Q3 25
1.24×
Q2 25
0.26×
Q1 25
0.59×
Q4 24
Q3 24
16.87×
Q2 24
0.45×
Q1 24
1.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons